Abstracts Archive - Page 1667 of 2425 - ACR Meeting Abstracts

Abstract Number: 2925 • 2015 ACR/ARHP Annual Meeting
Factors Associated with Early Damage Accrual in Patients with Systemic Lupus Erythematosus: 12-Month Preliminary Results from the Inception Cohort of the Multicenter Early Lupus Project
Matteo Piga¹, Fabiana Figus¹, Francesca Bellisai², Silvano Bettio³, Alessandra Bortoluzzi⁴, Laura Coladonato⁵, Fabrizio Conti⁶, Andrea Doria³, Mauro Galeazzi², Marcello Govoni⁴, Florenzo Iannone⁷, Annamaria Iuliano⁸, Marta Mosca⁹, Imma Prevete⁸, Gian Domenico Sebastiani⁸, Francesca Romana Spinelli¹⁰, Chiara Tani⁹ and Alessandro Mathieu¹, ¹University of Cagliari, Cagliari, Italy, ²University of Siena, Siena, Italy, ³Department of Medicine-DIMED, University of Padova, Padova, Italy, ⁴University of Ferrara, Ferrara, Italy, ⁵DIM, Rheumatology Unit, Bari, Italy, ⁶Rheumatology Unit, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Rome, Italy, ⁷Interdisciplinary Department of Medicine (DIM), Rheumatology Unit, University of Bari, Bari, Italy, ⁸Osp. San Camillo, Roma, Italy, ⁹University of Pisa, Pisa, Italy, ¹⁰Sapienza University of Rome, Rome, Italy
Background/Purpose: Preventing organ damage is a major challenge in management of Systemic Lupus Erythematosus (SLE). Few data are available on factors related to development of…
Abstract Number: 2926 • 2015 ACR/ARHP Annual Meeting
Cytochrome P450 Polymorphisms on Blood Hydroxychloroquine Levels in Patients with Systemic Lupus Erythematosus
Ji Yeon Lee¹, Min Kyung Chung², Ji Hun Kim², Jung Hee Koh³, Seung Min Jung⁴, Jennifer Lee², Seung-Ki Kwok⁵, Ji Hyeon Ju⁶, Kyung-Su Park⁷ and Sung-Hwan Park², ¹Division of Rheumatology, Department of Internal Medicine, School of Medicine, Catholic University of Korea, Seoul St. Mary’s Hospital, Seoul, South Korea, ²Division of Rheumatology, Department of Internal Medicine, College of Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, South Korea, ³Division of Rheumatology, Department of Internal Medicine, School of Medicine, The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, South Korea, ⁴Division of Rheumatology, Department of Internal Medicine, school of medicine, The catholic university of Korea, Seoul, South Korea, ⁵[email protected], Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ⁶Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ⁷Division of Rheumatology, Internal Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea
Background/Purpose: Hydroxychloroquine (HCQ) is a safe and effective treatment for systemic lupus erythematosus (SLE), and its blood concentration is known to be closely related to…
Abstract Number: 2927 • 2015 ACR/ARHP Annual Meeting
Disease Activity Patterns over Time in Patients with SLE – a Retrospective Descriptive Analysis of the Hopkins Lupus Cohort
Noémi Györi¹, Katerina Chatzidionysiou², Laurence S Magder³, Ronald F. van Vollenhoven¹ and Michelle Petri⁴, ¹Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ²Department of Medicine, Unit of Rheumatology, Department of Medicine Solna, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ³Johns Hopkins University School of Medicine, Devision of Rheumatology, Baltimore, MD, ⁴Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a multi-systemic inflammatory disease, characterized by an extreme variability of its expression, both between and within individuals, over time.…
Abstract Number: 2928 • 2015 ACR/ARHP Annual Meeting
Persistent Disease Activity over Time in a Large Canadian Cohort of Prevalent Lupus Patients
Christine A. Peschken¹, Willy Wynant², Michal Abrahamowicz³, Janet E. Pope⁴, Earl Silverman⁵, Amyn Sayani⁶, Sandra Iczkovitz⁶, Jorge A. Ross⁶, Christian Pineau⁷, C Douglas Smith⁸, Marie Hudson⁷, Michel Zummer⁹, Lori B. Tucker¹⁰, Deborah M. Levy¹¹, Gaëlle Chédeville¹², Adam M. Huber¹³, Hector Arbillaga¹⁴, Carol Hitchon¹⁵, Paul R. Fortin¹⁶ and CaNIOS 1000 Faces Investigators, ¹Arthritis Center, University of Manitoba, Winnipeg, MB, Canada, ²McGill University, Quebec, QC, Canada, ³Department of Epidemiology and Biostatistics., McGill University, Montreal, QC, Canada, ⁴University of Western Ontario, London, ON, Canada, ⁵Division of Rheumatology, Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ⁶Medical Affairs, GlaxoSmithKline, Mississauga, ON, Canada, ⁷Medicine, McGill University, Montreal, QC, Canada, ⁸The Arthritis Centre, TOH Riverside Campus, Ottawa, ON, Canada, ⁹Rheumatology, Hôpital Maisonneuve-Rosemont and University of Montreal, Montreal, QC, Canada, ¹⁰Rheumatology, BC Children's Hospital, Vancouver, BC, Canada, ¹¹Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ¹²Rheumatology, McGill University, Montreal, QC, Canada, ¹³Pediatric rheumatology, IWK Health Centre, Halifax, NS, Canada, ¹⁴Calgary Rheumatology, Calgary, AB, Canada, ¹⁵University of Manitoba, Winnipeg, MB, Canada, ¹⁶Medicine, CHU de Québec - Université Laval, Québec, QC, Canada
Background/Purpose: Treatment of systemic lupus erythematosus (SLE) aims at controlling disease activity to prevent damage. In a large multi-centre cohort of prevalent SLE patients we…
Abstract Number: 2929 • 2015 ACR/ARHP Annual Meeting
Diet and Glucocorticoid Treatment in Patients with SLE
Cecilia Lourdudoss¹, Johan Frostegård² and Ronald F. van Vollenhoven³, ¹Dept. of Medicine, ClinTRID, Karolinska institutet, Stockholm, Sweden, ²Karolinska Institutet, Section of Immunology and chronic disease, Institute of Environmental Medicine, Stockholm, Sweden, ³Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden
Background/Purpose: Relatively little is known about the link between diet and treatment results in SLE. Glucocorticoids (GC) are used to control active SLE but minimized…
Abstract Number: 2930 • 2015 ACR/ARHP Annual Meeting
Outcome of Patients with Systemic Lupus Erythematous (SLE) after Thrombotic Events
Samar Alharbi¹, Jiandong Su², Stacey E. Morrison³, Mohammed Attar⁴, Khawla Al-Ghanim⁵, Murray Urowitz^6,7, Dafna Gladman² and Jorge Sánchez-Guerrero⁸, ¹Rheumatology, University Health Network, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Div Rheumatology Rm MP-10-304, Toronto Western Hospital, Toronto, ON, Canada, ⁴Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, ⁵Rheumatology, TWH, Toronto, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada, ⁷Rheumatology, U of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁸Rheumatology, Mount Sinai Hospital and University Health Network, Toronto Canada, Toronto, ON, Canada
Background/Purpose: To assess the impact of thrombotic events (TE) on 1) mortality, 2) SLE-related damage accrual; and 3) health-related quality of life (HRQoL) in patients…
Abstract Number: 2931 • 2015 ACR/ARHP Annual Meeting
Is Pregnancy a Risk Factor for the Onset of Systemic Lupus Erythematosus (SLE) in Women of the Reproductive Age: A Population Based Case-Control Study?
Chi Chiu Mok¹, Sau Mei Tse¹, Ling Yin Ho² and Kar Li Chan¹, ¹Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, ²Dept of Medicine, Tuen Mun Hospital, Hong Kong SAR, Hong Kong
Background/Purpose: To evaluate whether pregnancy is a risk factor for the onset of SLE in women of the reproductive age.Methods: Female patients who had first…
Abstract Number: 2932 • 2015 ACR/ARHP Annual Meeting
A Retrospective Observational Study of Patients with Lupus Nephritis Treated with Rituximab in Combination with Cyclophosphamide
Nídia Oliveira¹, Mónica Ibañez², Natalia Ciang³ and David A. Isenberg⁴, ¹Internal Medicine Department, Hospital Pedro Hispano, Matosinhos, Portugal, London, United Kingdom, ²Rheumatology Department, Hospital Son Llàtzer, Palma de Mallorca, Spain, London, United Kingdom, ³Rheumatology Department, Queen Eliazbeth Hospital, Hong Kong, London, United Kingdom, ⁴Rayne Institute, Centre for Rheumatology Research, UCL Division of Medicine, London, United Kingdom
Background/Purpose: Lupus nephritis (LN) is a major cause of morbidity. Many patients with refractory disease can not tolerate conventional immunosuppressive therapy. The aims of this…
Abstract Number: 2933 • 2015 ACR/ARHP Annual Meeting
Low Prevalence of PCP in Hospitalized Patients with SLE: Review of a Clinical Database Warehouse
Teja Kapoor¹, Jianhua Li², Sameer Malhotra³, Joan Bathon⁴ and Anca Askanase⁵, ¹Columbia University, New York, NY, ²Columbia University Medical Center, New York, NY, ³Weill Cornell Medical Center, New York, NY, ⁴Rheumatology, Columbia University Medical Center, NY, NY, ⁵Columbia University College of Physicians & Surgeons, New York, NY
Background/Purpose : The risk of Pneumocystis carinii pneumonia (PCP) in Systemic Lupus Erythematosus (SLE) is not well-established. Accordingly, this study aims to establish the prevalence…
Abstract Number: 2934 • 2015 ACR/ARHP Annual Meeting
Endothelial Dysfunction in SLE-the Role of Platelets and Type I Interferon
Helena Tydén¹, Christian Lood², Birgitta Gullstrand³, Andreas Jönsen⁴ and Anders A. Bengtsson⁵, ¹Department of Clinical Sciences, Division of Rheumatology Lund University and Skane University Hospital Lund Sweden, Lund University, Lund, Sweden, ²Department of Clinical Sciences, Division of Rheumatology, Lund University and Skane University Hospital Lund Sweden, Lund University, Lund, Sweden, ³Department of Clinical Sciences, Division of Rheumatology Lund University and Skane University Hospital, Lund University, Lund, Sweden, ⁴Department of Rheumatology, Lund University Hospital, Lund, Sweden, ⁵Rheumatology, Inst of Clinical sciences, Lund, Sweden
Background/Purpose: Type I interferon (IFN) may affect endothelial progenitor cells leading to endothelial dysfunction in SLE. SLE patients have a type I IFN signature in…
Abstract Number: 2935 • 2015 ACR/ARHP Annual Meeting
Disease Evolution in Late Onset and Early Onset Systemic Lupus Erythematosus (SLE)
Roa'a Al Johani¹, Dafna Gladman², Jiandong Su² and Murray Urowitz^2,3, ¹Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Rheumatology, U of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: To compare clinical features, disease activity and outcome in late onset versus early onset SLE over 5 years of follow up. Methods: Patients with…
Abstract Number: 2936 • 2015 ACR/ARHP Annual Meeting
Evolution of Disease Burden over 7 Years in a Multicentre Inception SLE Cohort
Murray Urowitz^1,2, Dafna Gladman¹, Nicole Anderson³, Jiandong Su¹ and Systemic Lupus Erythematosus International Collaborating Clinics (SLICC), ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, U of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: The evolution on an annual basis of disease activity and damage and the annual accrual of ACR criteria and key autoantibodies in patients with…
Abstract Number: 2937 • 2015 ACR/ARHP Annual Meeting
Treatment Patterns Differ Based on Age of Systemic Lupus Erythematosus Onset: A Comparison of Azathioprine and Mycophenolate on the Prevention of Lupus Nephritis
J. Madison Hyer¹, Bethany Wolf¹, Jim Oates², Gary S. Gilkeson³ and Diane L. Kamen², ¹Public Health Sciences, Medical University of South Carolina, Charleston, SC, ²Medicine, Medical University of South Carolina, Charleston, SC, ³Department of Rheumatology, Medical University of South Carolina, Charleston, SC
Background/Purpose: Lupus nephritis (LN) is a major cause of morbidity and mortality among patients with systemic lupus erythematous (SLE). Studies have demonstrated efficacy and safety…
Abstract Number: 2938 • 2015 ACR/ARHP Annual Meeting
Baseline Predictors of Remission and Low Disease Activity Using Recently Defined International Criteria in a Multi-Center Lupus Registry Cohort
Kichul Ko¹, Alana B. Levine², Russell Griffin³, Olga Dvorkina⁴, Saira Sheikh⁵, Jinoos Yazdany⁶, Richard Furie⁷ and Cynthia Aranow⁸, ¹Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, IL, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Medicine, SUNY Health Science Center at Brooklyn, Brooklyn, NY, ⁵University of North Carolina, Chapel Hill, NC, ⁶Rheumatology, University of California, San Francisco, San Francisco, CA, ⁷Division of Rheumatology, North Shore - LIJ Health System, New York, NY, ⁸Feinstein Institute for Medical Research, Mahasset, NY
Background/Purpose: Treating to a target of remission or low disease activity state (LDAS) is an attractive potential therapeutic approach in SLE. Recently, LDAS and remission…
Abstract Number: 2939 • 2015 ACR/ARHP Annual Meeting
The Impact of Tabalumab on the Kidney in Systemic Lupus Erythematosus: Results from Two Phase 3 Randomized Clinical Trials
Mary Anne Dooley¹, Brad H. Rovin², Jai Radhakrishnan³, Ellen M. Ginzler⁴, Tammy Forrester⁵ and Pamela Anderson⁶, ¹Medicine-Rheumatology-Immun, U of NC at Chapel Hill, Chapel Hill, NC, ²Ohio State University Medical Center, Columbus, OH, ³Presbyterian Hospital, Columbia University, New York, NY, ⁴Medicine/Box 42, SUNY-Downstate, Brooklyn, NY, ⁵Eli Lilly & Company, Indianapolis, IN, ⁶Eli Lilly & Co, Indianapolis, IN
Background/Purpose: Tabalumab is a monoclonal antibody that neutralizes membrane and soluble B-cell activating factor. Two 52-week, randomized, double-blinded, placebo-controlled Phase 3 trials, designated BCDS and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].